William Blair & Company
TVTX icon

William Blair & Company’s Travere Therapeutics TVTX Stock Holding History

William Blair & Company’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,000
Closed -$230K – 1786
2018
Q3 		$230K Hold
8,000
– – ﹤0.01% 1239
2018
Q2 		$218K Buy
+8,000
New +$213K ﹤0.01% 1240

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

William Blair & Company's TVTX Position: Q4 2018 in Review

William Blair & Company sold out of Travere Therapeutics (TVTX) in Q4 2018, closing a stake of 8,000 shares — an estimated $230K sold.

William Blair & Company first reported a position in TVTX in Q2 2018 and held it in 2 quarters. The position peaked at $230K in Q3 2018. 130 funds tracked by Wall St. Rank hold TVTX as of Q4 2018.

  • William Blair & Company reported no remaining Travere Therapeutics position as of Q4 2018 after selling out during the quarter.
  • William Blair & Company sold 8,000 Travere Therapeutics shares in Q4 2018, an estimated $230K.
  • William Blair & Company first reported a position in Travere Therapeutics in Q2 2018 and held it in 2 quarters.
  • William Blair & Company's Travere Therapeutics position peaked at $230K in Q3 2018.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2018.

Based on William Blair & Company's 13F filing for Q4 2018, filed 14 Feb 2019.